APG-115
A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 69 patients (estimated)
- Sponsors
- Ascentage Pharma Group Inc.
- Tags
- Antimetabolites, Hypomethylating Agents (HMA), MDM2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1371
- NCT Identifier
- NCT04358393
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.